secwatch.observer — SEC 8-K summary
======================================

Issuer:     BAXTER INTERNATIONAL INC (BAX)
CIK:        0000010456
Form:       8-K
Filed at:   2024-11-08T23:59:59+00:00
Accession:  0001628280-24-046501
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Baxter Q3 2024: continuing ops sales +4% to $2.7B; adj. EPS $0.80 beats guidance
--------------------------------------------------------------------------------

- Total sales (incl. discontinued ops) $3.85B; continuing ops sales $2.70B +4% YoY.
- GAAP diluted EPS from continuing ops $0.12; adjusted continuing ops EPS $0.49.
- Total Baxter GAAP diluted EPS $0.27; adjusted total diluted EPS $0.80, exceeding prior guidance.
- North Cove facility restarted highest-throughput IV solutions line after Hurricane Helene.
- Pending sale of Kidney Care business is a key milestone; hurricane expected to impact near-term financials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/10456/000162828024046501/0001628280-24-046501-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/10456/000162828024046501/bax-20241108.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-046501

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer